Pathological manifestations of inflammatory microthrombosis in COVID-19

Abstract

Background. COVID-19 is a predominantly respiratory disease caused by the SARS-CoV-2 virus that has spread as a pandemic since 2020; characterized by high mortality and unexplored long-term outcomes.

Aim. To describe the morphological changes in the lungs and other organs in severe forms of COVID-19.

Material and methods. A macro- and microscopic examination of the lungs, kidneys, liver, brain and heart of 45 patients who died from complications of COVID-19 was carried out. Histological preparations were stained with hematoxylin and eosin, by the Picro-Mallory stain, as well as with fluorescent antibodies and dyes to visualize neutrophil extracellular traps.

Results. The leading pathomorphological manifestations of COVID-19 were inflammation and microthrombosis in the lungs. At the same time, diffuse alveolar damage often developed as a manifestation of acute respiratory distress syndrome in an adult. Diffuse leukocyte infiltration of the lungs was combined with the formation of neutrophil extracellular traps in the lumens of the blood vessels. Diffuse microthrombi were found in most lung tissue samples (87%), while macroscopic thrombi were much less common (16%). In single cases, the cause of death was thromboembolism of the branches of the pulmonary artery, originating from deep vein thrombi of the lower extremities or the right atrial appendage. In the tissues of the liver, heart, kidneys and brain, moderate alterative (degenerative and necrobiotic) microscopic changes were observed, as well as morphological signs of concomitant chronic diseases.

Conclusion. COVID-19 is characterized by pathogenically interrelated morphological manifestations of inflammation and primary pulmonary (micro)thrombosis in the form of accumulation of leukocytes both in blood clots and in the alveoli, while regional pulmonary immunothrombosis is associated with diffuse damage to the alveoli; in the heart, brain, liver and kidneys, predominantly dystrophic and necrobiotic changes occur, which are typical of secondary injuries and/or concomitant pathology.

Keywords

thrombosis / COVID-19 / inflammation

References

[1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. DOI: 10.1038/s41586-020-2012-7.

[2] Zairatians OV, editor. Patologicheskaya anatomiya COVID-19. Atlas. (Pathalogical anatomy of COVID-19: Atlas.) M.: GBU “NIIOZMM DZM”; 2020. 140 p. (In Russ.)

[3] Патологическая анатомия COVID-19. Атлас. Под общей ред. О.В. Зайратьянца. М.: ГБУ «НИИОЗММ ДЗМ»; 2020. 140 с.

[4] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099. DOI: 10.1111/jth.14817.

[5] Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost. 2020;46:777–780. DOI: 10.1055/s-0040-1712155.

[6] Becker RC. COVID-19 update: COVID-19-associa¬ted coagulopathy. J Thromb Thrombolysis. 2020;50:54–67. DOI: 10.1007/s11239-020-02134-3.

[7] Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-associated coagulopathy: An exacerbated immunothrombosis response. Clin Appl Thromb Hemost. 2020;26:1076029620943293. DOI: 10.1177/1076029620943293.

[8] Temporary guidelines “Prevention, diagnosis and treatment of the new coronavirus infection (COVID-19)”. Ministry of Health of the Russian Federation. Version 12 (21.09.2021). 232 р. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf (access date: 21.10.2021). (In Russ.)

[9] Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Министерство здравоохранения РФ. Версия 12 (21.09.2021). 232 с. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf (дата обращения: 21.10.2021).

[10] Khismatullin RR, Shakirova AZ, Weisel JW, Litvi¬nov RI. Age-dependent differential staining of fibrin in blood clots and thrombi. BioNanoScience. 2020;10:370–374. DOI: 10.1007/s12668-019-00701-4.

[11] Zinserling VA, Vashukova MA, Vasilyeva MV, Isakov AN, Lugovskaya NA, Narkevich TA, Sukhanova YuV, Semenova NYu, Gusev DA. Issues of pathology of a new coronavirus infection COVID-19. Journal Infectology. 2020;12(2):5–11. (In Russ.) DOI: 10.22625/2072-6732-2020-12-2-5-11.

[12] Цинзерлинг В.А., Вашукова М.А., Васильева М.В., Исаков А.Н., Луговская Н.А., Наркевич Т.А., Суханова Ю.В., Семенова Н.Ю., Гусев Д.А. Вопросы патоморфогенеза новой коронавирусной инфекции (COVID-19). Журнал инфектологии. 2020;12(2):5–11. DOI: 10.22625/2072-6732-2020-12-2-5-11.

[13] Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168–175. DOI: 10.1161/01.atv.0000051384.43104.fc.

[14] Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268–277. DOI: 10.7326/M20-2003.

[15] Zairat’yants OV, Kakturskiy LV. Formulirovka i sopostavleniye klinicheskogo i patologoanatomiches¬kogo diagnozov: Spravochnik. (Formulation and matching of clinical and pathoanatomical diagnosis. Handbook.) 2nd ed. M.: Me¬ditsinskoye informatsionnoye agentstvo; 2011. 576 p. (In Russ.)

[16] Зайратьянц О.В., Кактурский Л.В. Формулировка и сопоставление клинического и патологоанатомического диагнозов. Справочник. Изд. 2-е, перераб. и доп. М.: Медицинское информационное агентство; 2011. 576 с.

[17] Páramo JA. Pulmonary embolism, pulmonary microvascular thrombosis, or both in COVID-19? Clin Appl Thromb Hemost. 2020;26:1076029620933953. DOI: 10.1177/1076029620933953.

[18] Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. DOI: 10.1016/j.thromres.2020.04.013.

[19] Cardinal-Fernández P, Lorente JA, Ballén-Barragán A, Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship. Ann Am Thorac Soc. 2017;14:844–850. DOI: 10.1513/AnnalsATS.201609-728PS.

[20] Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, Mostyka M, Baxter-Stoltzfus A, Borczuk AC, Loda M, Cody MJ, Manne BK, Portier I, Harris ES, Petrey AC, Beswick EJ, Caulin AF, Iovino A, Abegglen LM, Weyrich AS, Rondina MT, Egeblad M, Schiffman JD, Yost CC. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179. DOI: 10.1182/blood.2020007008.

[21] Janiuk K, Jabłońska E, Garley M. Significance of NETs formation in COVID-19. Cells. 2021;10:151. DOI: 10.3390/cells10010151.

[22] Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. COVID-19: the rollercoaster of fibrin(ogen), D-dimer, von Willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020;21:5168. DOI: 10.3390/ijms21145168.

Funding

Работа выполнена за счёт средств Программы стратегического академического лидерства (Приоритет-2030) Казанского (Приволжского) федерального университета, гранта Российского научного фонда 21-75-00010 и грантов Российского фонда фундаментальных исследований 19-015-00075 и 20-015-00257

RIGHTS & PERMISSIONS

Eco-Vector